Completed PHASE2 INTERVENTIONAL 1-arm NCT00336856

Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy

A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer

Sponsor: Bristol-Myers Squibb

Conditions Colon Cancer Rectum Cancer

Interventions Cetuximab Irinotecan

Updated 5 times since 2017 Last updated: Jun 1, 2016 Started: Jun 30, 2006 Primary completion: Jun 30, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Colon Cancer and Rectum Cancer, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 5 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
University of Pittsburgh

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States